Latest News and Press Releases

AstraZeneca PLC H1 2016 Results Tomorrow, Thursday 28 July 2016, AstraZeneca PLC will publish its H1 2016 results at 07:00 UK time. An analyst presentation will take place at 12:00 UK time and will...

This announcement contains inside information 19 July 2016 14:15 ASTRAZENECA RECEIVES APPROVAL IN THE EU FOR QTERN (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR TREATMENT OF TYPE 2 DIABETES AstraZeneca...

Tagrisso demonstrated superior progression-free survival compared to standard platinum-based chemotherapy, with a safety profile consistent with previous trials First randomised trial to evaluate the...

This announcement contains inside information 13 July 2016 07:00 ASTRAZENECA ENTERS INTO AGREEMENT TO RESOLVE FASLODEX PATENT LITIGATION IN THE US AstraZeneca today announced that it has entered...

ASTRAZENECA ENTERS LICENSING AGREEMENTS WITH LEO PHARMA IN SKIN DISEASES Agreement for development and commercialisation of tralokinumab for atopic dermatitis supports sharper focus on main therapy...

28 June 2016 AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination...

AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of...

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 13 June 2016, the interest of Pascal Soriot, a person discharging managerial responsibilities, in the...

ASTRAZENECA ENTERS COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETIC MEDICINES PORTFOLIO Agreement expands commercial reach for anaesthetics and supports the Company's sharp focus on innovative...

AstraZeneca today announced that it has completed the...